PALO ALTO, Calif.--Incyte Pharmaceuticals has signed a multiyear genomic database partnership that will provide Glaxo Wellcome with access to specific LifeSeq database products in exchange for annual access fees, and could yield royalty payments to Incyte from sales of products developed with Incyte's products and database information.
The deal gives Glaxo Wellcome access to the database at eight research sites, including Research Triangle Park, N.C.; the Geneva Biomedical Research Institute; the Glaxo Wellcome Medicines Research Center in Stevenage, U.K.; and Affymax Research Institute here.